Tomokazu Aoki

Summary

Affiliation: Kitano Hospital
Country: Japan

Publications

  1. ncbi A first feasibility study of temozolomide for Japanese patients with recurrent anaplastic astrocytoma and glioblastoma multiforme
    Tomokazu Aoki
    Department of Neurosurgery, Kitano Hospital, 2 4 20 Ohgimachi, Kita ku, 530 8480, Osaka, Japan
    Int J Clin Oncol 8:301-4. 2003
  2. ncbi Phase II study of ifosfamide, carboplatin, and etoposide in patients with a first recurrence of glioblastoma multiforme
    Tomokazu Aoki
    Department of Neurosurgery, Kitano Hospital Medical Research Institute, Osaka, Japan
    J Neurosurg 112:50-6. 2010
  3. ncbi Management of glioblastoma
    Tomokazu Aoki
    Kitano Hospital, Department of Neurosurgery, Brain Tumour Center, 2 4 20 Ohgimachi, Kita ku, Osaka, Japan
    Expert Opin Pharmacother 8:3133-46. 2007
  4. ncbi Pharmacokinetic study of temozolomide on a daily-for-5-days schedule in Japanese patients with relapsed malignant gliomas: first study in Asians
    Tomokazu Aoki
    Department of Neurosurgery, Kitano Hospital Medical Research Institute, 2 4 2 Ogimachi, Kita ku, Osaka 530 8480, Japan
    Int J Clin Oncol 12:341-9. 2007
  5. ncbi Phase II study of nimustine, carboplatin, vincristine, and interferon-beta with radiotherapy for glioblastoma multiforme: experience of the Kyoto Neuro-Oncology Group
    Tomokazu Aoki
    Department of Neurosurgery, Kitano Hospital Medical Research Institute, Osaka, Japan
    J Neurosurg 105:385-91. 2006
  6. ncbi A multicenter phase I trial of combination therapy with interferon-? and temozolomide for high-grade gliomas (INTEGRA study): the final report
    Toshihiko Wakabayashi
    Department of Neurosurgery, Nagoya University School of Medicine, 65 Tsurumai Cho, Showa Ku, Nagoya, 466 8550, Japan
    J Neurooncol 104:573-7. 2011
  7. ncbi A multicenter phase I trial of interferon-beta and temozolomide combination therapy for high-grade gliomas (INTEGRA Study)
    Toshihiko Wakabayashi
    Department of Neurosurgery, Nagoya University School of Medicine, Nagoya, Japan
    Jpn J Clin Oncol 38:715-8. 2008
  8. ncbi Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen--A24 with recurrent or progressive glioblastoma multiforme
    Mizuhiko Terasaki
    Department of Neurosurgery, Kurume University School of Medicine, 67 Asahi Machi, Kurume, Fukuoka 830 0011, Japan
    J Clin Oncol 29:337-44. 2011
  9. ncbi [Efficacy and safety of monotherapy with temozolomide in patients with anaplastic astrocytoma at first relapse--a phase II clinical study]
    Ryo Nishikawa
    Dept. of Neurosurgery, Saitama Medical University
    Gan To Kagaku Ryoho 33:1279-85. 2006
  10. ncbi [Chemoradiotherapies for malignant gliomas]
    Tomokazu Aoki
    Division of Neurosurgery, Kitano Hospital
    Nippon Rinsho 63:472-7. 2005

Detail Information

Publications10

  1. ncbi A first feasibility study of temozolomide for Japanese patients with recurrent anaplastic astrocytoma and glioblastoma multiforme
    Tomokazu Aoki
    Department of Neurosurgery, Kitano Hospital, 2 4 20 Ohgimachi, Kita ku, 530 8480, Osaka, Japan
    Int J Clin Oncol 8:301-4. 2003
    ..We report a feasibility study of the palliative efficacy of temozolomide for patients with recurrent anaplastic astrocytoma (AA) and glioblastoma multiforme (GBM)...
  2. ncbi Phase II study of ifosfamide, carboplatin, and etoposide in patients with a first recurrence of glioblastoma multiforme
    Tomokazu Aoki
    Department of Neurosurgery, Kitano Hospital Medical Research Institute, Osaka, Japan
    J Neurosurg 112:50-6. 2010
    ..The authors conducted a Phase II study of ifosfamide, carboplatin, and etoposide (ICE) for a first recurrence of GBM to determine whether it prolonged a patient's good-quality life...
  3. ncbi Management of glioblastoma
    Tomokazu Aoki
    Kitano Hospital, Department of Neurosurgery, Brain Tumour Center, 2 4 20 Ohgimachi, Kita ku, Osaka, Japan
    Expert Opin Pharmacother 8:3133-46. 2007
    ..Patients require improvements in chemotherapy, surgery, radiotherapy, molecular targeted therapy, immunotoxin using the convection-enhanced delivery and more...
  4. ncbi Pharmacokinetic study of temozolomide on a daily-for-5-days schedule in Japanese patients with relapsed malignant gliomas: first study in Asians
    Tomokazu Aoki
    Department of Neurosurgery, Kitano Hospital Medical Research Institute, 2 4 2 Ogimachi, Kita ku, Osaka 530 8480, Japan
    Int J Clin Oncol 12:341-9. 2007
    ..Temozolomide (TMZ) is widely used in Europe and the United States. For the safe use of TMZ in the Japanese, as representative of Asians, the pharmacokinetics of TMZ was investigated in Japanese patients and compared to that in Caucasians...
  5. ncbi Phase II study of nimustine, carboplatin, vincristine, and interferon-beta with radiotherapy for glioblastoma multiforme: experience of the Kyoto Neuro-Oncology Group
    Tomokazu Aoki
    Department of Neurosurgery, Kitano Hospital Medical Research Institute, Osaka, Japan
    J Neurosurg 105:385-91. 2006
    ..This Phase II study was performed to determine the safety, tolerability, and efficacy of combining nimustine (ACNU)-carboplatin-vincristine-Interferon-beta (IFNbeta) chemotherapy...
  6. ncbi A multicenter phase I trial of combination therapy with interferon-? and temozolomide for high-grade gliomas (INTEGRA study): the final report
    Toshihiko Wakabayashi
    Department of Neurosurgery, Nagoya University School of Medicine, 65 Tsurumai Cho, Showa Ku, Nagoya, 466 8550, Japan
    J Neurooncol 104:573-7. 2011
    ..We conclude that this regimen is safe and well tolerated and may prolong survival of patients with glioblastoma. A phase II clinical study is essential to corroborate our findings...
  7. ncbi A multicenter phase I trial of interferon-beta and temozolomide combination therapy for high-grade gliomas (INTEGRA Study)
    Toshihiko Wakabayashi
    Department of Neurosurgery, Nagoya University School of Medicine, Nagoya, Japan
    Jpn J Clin Oncol 38:715-8. 2008
    ..Subsequently, the overall response will be evaluated based on the results of measurable and non-measurable tumors. Ten newly diagnosed and 10 recurrent patients will be enrolled in this study...
  8. ncbi Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen--A24 with recurrent or progressive glioblastoma multiforme
    Mizuhiko Terasaki
    Department of Neurosurgery, Kurume University School of Medicine, 67 Asahi Machi, Kurume, Fukuoka 830 0011, Japan
    J Clin Oncol 29:337-44. 2011
    ..We present the results of a phase I trial of 14 kinds of vaccine candidates (ITK-1) in patients with recurrent or progressive glioblastoma multiforme (GBM)...
  9. ncbi [Efficacy and safety of monotherapy with temozolomide in patients with anaplastic astrocytoma at first relapse--a phase II clinical study]
    Ryo Nishikawa
    Dept. of Neurosurgery, Saitama Medical University
    Gan To Kagaku Ryoho 33:1279-85. 2006
    ..Temozolomide was shown to have good efficacy and tolerability in patients with anaplastic astrocytoma at first relapse...
  10. ncbi [Chemoradiotherapies for malignant gliomas]
    Tomokazu Aoki
    Division of Neurosurgery, Kitano Hospital
    Nippon Rinsho 63:472-7. 2005